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Abstract
Introduction: Two types of gliomatosis cerebri exist: Type I and Type II. We report the results of a
histological and genetic study of two cases of gliomatosis cerebri Type II, correlating these results
with therapy and prognosis.
Case presentation: Two patients, a 52-year-old man (Patient 1) and a 76-year-old man (Patient 2)
with gliomatosis cerebri II were admitted to our institution; they underwent surgical treatment and
received radiotherapy and chemotherapy. At the 24-month follow-up, Patient 1 was still alive, while
Patient 2 had died. The poor prognosis of Patient 2 was underlined by molecular analysis which
showed that the angiogenesis related genes VCAM1 and VEGF were overexpressed, reflecting the high
degree of neovascularization.
Conclusion: Genes involved in drug resistance and metallothioneins were highly expressed in
Patient 2 and this, associated with unmethylated O6-methylguanine methyltransferase, can explain the
lack of response to chemotherapy.
Introduction
Gliomatosis cerebri (GC) is a diffuse, frequently bilateral,
glial tumor which infiltrates the brain, involving more
than two lobes. It often extends to the infratentorial
structures and even to the spinal cord. According to the
current WHO classification of brain tumors, GC is a
distinct malignant neuroepithelial neoplasm of uncertain
origin [1]. Pathologists describe two types of GC: Type I is
the classic form of GC characterized by diffuse overgrowth
with neoplastic glial elements without a focal mass
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ized by a diffuse brain infiltration and focal mass presence,
usually a high-grade glioma [1]. More than 200 cases of
GC have been described in the literature, but very few cases
of Type II GC have been genetically typed. We report the
results of a histological and genetic study in two cases of
gliomatosis cerebri Type II. A prognostic correlation of
these results is also provided.
Case presentation
TwopatientsofItalianethnicity,a52-year-oldman(Patient1)
and a 76-year-old man (Patient 2), with clinical signs of
increased intracranial pressure were admitted to our
institution. Pre-operative neuroradiological studies (com-
puted tomography (CT) scan and magnetic resonance
imaging (MRI)) were performed. The patients underwent
surgical treatment and received radiotherapy at a 54.9 Gy
dose and concomitant chemotherapy with temozolomide.
Fresh surgical specimens were frozen in liquid nitrogen
immediately after removal, and were treated immediately
upon arrival at the laboratory. Isolation of DNA from
these specimens was performed using the ChargeSwitch®
gDNA Micro Tissue Kit (Invitrogen, Karlsruhe, Germany).
Isolation of total RNA from the surgical specimens was
performed using the PureLink™ Micro-toMidi™ Total RNA
Purification System following the manufacturer’s instruc-
tions (Invitrogen).
TP53 exons 5-8 and all PTEN exons were analyzed by the
sequencing of various tumor regions. Each exon was
polymerase chain reaction (PCR) amplified. Sequence
reactions were performed with a BigDye® Terminator v3.1-
kit (Applied Biosystems, Warrington, UK) using both
forward and reverse primers. Finally, the sequences were
read by an automated sequence reader (ABI PRISM 3130,
Applied Biosystems).
For CGH analysis, a custom 60-mer amino modified
oligo-microarray was used, containing 6000 spots, specific
to 287 chromosomal regions implicated in cancer.
Labeling reactions were performed on purified restricted
DNA using the BioPrime Array CGH Genomic Labeling
System (Invitrogen). Experimental and reference targets
were hybridized for 14 to 18 hours at 42°C. After washing,
slides were scanned using an Affymetrix 428 array scanner
(Affymetrix, Santa Clara, CA, USA).
For LOH analysis, a custom 30-mer amino modified oligo-
micro array was used. Single nucleotide polymorphisms
(SNPs) were chosen to represent markers for 2q14.3,
2q22.1, 3q13, 7q22, 10q22-10q23, 12q14, 13q14, 16q22
17p.13.1, and 19q13.2. Two 30-mer oligonucleotides per
locus were designed to represent the alternate alleles
of each SNP. Each oligonucleotide consisted of a
12-nucleotide hairpin and an 18- to 21-nucleotide target
sequence with the polymorphic base in the middle.
A custom 60-mer amino modified oligo-array was used,
containing 800 probes specific for genes commonly
altered in cancer. RNA was labelled using the SuperScript
Indirect RNA Amplification System (Invitrogen). The
resulting amplified amino-allyl aRNA was dyed using
Cy3 for test samples and Cy5 for reference samples.
The microarray expression results were validated by
quantitative real-time PCR, using an ABI 7500 Real-Time
PCR System (Applied Biosystems). The Wilcoxon signed-
rank test was used to analyze statistical significance.
The DNA methylation patterns in the CpG island of the
O6-methylguanine-DNA methyltransferase (MGMT), p16,
deleted in colorectal cancer (DCC) and death-associated
protein kinase 1 (DAPK1) genes were determined by
sodium bisulfite treatment and subsequent methylation-
specific PCR MS PCR. Primers for MS PCR were designed
to encompass the CpG-rich area of the promoter region
around the transcription initiation site.
The neuroradiological studies (CT scan and MRI) indicated
gliomatosis cerebri Type II. Both patients underwent
surgical removal of the focal mass and biopsies in the
adjacent areas, and received temozolomide and radiation
therapy postoperatively. At the 24-month follow-up, after
chemo- and radiation therapy, Patient 1 was still alive with
impaired neurological conditions, while Patient 2 had died.
The histological study on the removed masses revealed a
diffuse proliferation of neoplastic spindle cells with rod-
shaped nuclei infiltrating the brain parenchyma in both
patients. Such cells appeared arranged in short chains
parallel to nervous fibers, in the shape of a high-grade
malignant neoplasm. These aspects were compatible with
the pre-operative diagnosis of gliomatosis cerebri Type II.
Paraffin-embedded sections were stained by the immuno-
peroxidase method which yielded the following results:
positive staining reaction to glial fibrillary acidic protein
(GFAP) and to S100 protein (Figure 1).
InPatient1,bidirectionalsequencingrevealedamutationin
codon248ofTP53,withargininetotryptophansubstitution
(Figure 2a). Patient 2 carried an intronic point mutation in
the PTEN gene, which altered the splice donor site within
intron 2 and therefore likely caused expression of an
aberrantlysplicedmRNA(Figure2b).Thesesamemutations
were observed in all of the tumor regions.
CGH analysis did not detect any CDKN2A (9p21) deletion
(confirmed by LOH) and no CDK4 or MDM2 amplifica-
tion in either patient. Patient 2 showed a gain in the EGFR
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the p27kip1 gene locus, no aberrations of CDKN1A (p21),
and losses of 2q, 3p, 16q and 19q and gains of 7q in both
patients (data not shown).
The results of cDNA gene expression profiling are reported
in Table 1, while Figure 3a shows a scatterplot with a
2-fold threshold. Genes found to be overexpressed were:
– transcriptional regulators (including ZNF258, EYA2,
EGR1, JUNB) and intracellular signal transduction genes
(RGS7, EHD3, CS1, ITPK1, GRB2, STK2) in both tumors;
– angiogenesis related genes (VCAM1, VEGF) and drug
resistance genes (ABCC3, MTIL) in Patient 2.
Genes found to be down-regulated were:
– signal transduction genes (PSHL, P1M1, IQGAP, RDC1,
RGS16) and cytoskeleton related genes (PFN1, MSN,
PLEK, VIM, CAPG) in Patient 2;
– apoptosis genes (CASP7, BCLW, DAP3 and DCC in line
with methylation status) in both tumors.
Figure 1. Histological study of the removed masses revealed a diffuse proliferation of neoplastic spindle cells with rod-shaped
nuclei infiltrating the brain parenchyma in both Patients 1 (a) and 2 (b). Paraffin-embedded sections were stained by the
immunoperoxidase method and were positive for glial fibrillary acidic protein (GFAP) (c) and S100 protein (d).
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Journal of Medical Case Reports 2009, 3:7225 http://jmedicalcasereports.com/jmedicalcasereports/article/view/7225Figure 2. (a) Sequence around codon 248 of TP53 showing the mutated base which determines an arginine to tryptophan
substitution. (b) The PTEN point mutation at the intron 2 splice donor site causes a defective splicing which likely results in a
non-functional protein.
Table 1. Microarray normalized data
Name Description I/C* Patient 1 I/C* Patient 2
Under-expressed in Patient 2
IQGAP IQ motif containing GTPase-activating protein 1 1.13 0.02
ITPK1 Inositol 1,3,4-triphosphate 5/6 kinase 1.5 1.6
P1M1 Pim-1 proto-oncogene gene 0.99 0.06
PSHL Phosphoserine phosphatase-like 1.0 0.12
PTGER4 Prostaglandin E receptor 4 (subtype EP4) 0.18 0.16
RDCl G protein-coupled receptor 1.0 0.11
RGS16 Regulator of G-protein signaling 16 1.12 0.06
CAPG Capping protein (actin filament), gelsolin-like 1.1 0.2
MSN Moesin 1.0 0.1
PFN1 Profilin 1 0.98 0.12
PLEK Plekstrin 1.12 0.11
VIM Vimentin 1.16 0.03
Over-expressed in Patient 2
VCAM1 Vascular cell adhesion molecule 1 1.01 4.8
VEGF Vascular endothelial growth factor 1.0 5.4
ABCC3 ATP-binding cassette C (CFTR/MRP) 1.09 8.0
MTIL Metallothionein 1L 1.1 9.9
EGFR Epidermal growth factor receptor 0.95 8.9
Over-expressed in Patient 1
p16^ink4a p16^ink4a 1.92 0.18
pRb pRb 1.8 0.21
Under-expressed in both patients
DCC Deleted in colorectal cancer 0.2 0.1
CASP7 Caspase 7, apoptosis-related cysteine protease 0.12 0.12
Bcl2-like 2 (Bcl-w) 0.15 0.14
DAP3 Death-associated protein 3 0.16 0.18
Over-expressed in both patients
EGR1 Early growth response 1 3.1 3.3
EYA2 Eyes absent (Drosophila) homolog 2 4.1 3.6
JUNB Jun B proto-oncogene 2.9 3.2
ZNF258 Zinc finger protein 258 5.0 6.1
RGS7 Regulator of G-protein signaling 7 15 17.2
EHD3 EH domain containing 3 12.1 13.3
CS-1 Calcineurin-binding protein calsarcin-1 9.8 10.2
ITPK1 Inositol 1,3,4-triphosphate 5/6 kinase 6.1 5.8
GRB2 Growth factor receptor-bound protein 2 3.1 3.4
STK2 Serine/threonine kinase 2 2.9 2.6
*I/C represents the normalized ratio between test channel and control channel.
Page 4 of 6
(page number not for citation purposes)
Journal of Medical Case Reports 2009, 3:7225 http://jmedicalcasereports.com/jmedicalcasereports/article/view/7225Interestingly, p16 and pRb were expressed in Patient 1 and
down-regulated in Patient 2, while EGFR was over-
expressed only in Patient 2.
QRT-PCR
Statistically significant changes in gene expression at the
P = 0.025 level were seen with all transcripts analyzed. The
results of real-time analysis are reported in Figure 3b.
Methylation analysis of MGMT, p16, DCC, DAPK1
DCC was found methylated in both tumors, MGMT
methylated only in Patient 1, in line with the chemother-
apy response, and p16 methylated only in Patient 2 since
this gene is under-expressed even if not mutated (Figure
4a). Primer sequences used in methylation-specific PCR
(MSP-PCR) are reported in Figure 4b.
Discussion
Unlike other cerebral gliomas, gliomatosis cerebri is a
particularly invasive glioma subform, characterized by
extraordinary brain spreading [2]. Like TP53 mutations,
molecular alterations in gliomatosis cerebri resemble those
detected in diffuse astrocytic gliomas [3]. Herrlinger et al.
described alterations not only in the TP53 gene, but also in
PTEN [2]. Our data seem to indicate a mutually exclusive
occurrence of both TP53 and PTEN mutations; in fact,
Patient 1 had a mutation of TP53 without any PTEN
alterationsandPatient2exhibitedaPTENmutationwithan
intact TP53. Genetic aberrations lack cell cycle regulatory
genes (CDKN2A, CDK4) and the strong expression of
p16INK4a and pRb suggests that the pRb-dependent cell
cyclecheckpointwasintactinPatient1.Patient2showedno
genomic aberrations on the CDKN2A locus, but had a
reducedp16expression;thus,tounderstandthemechanism
underlyingitsreducedexpression,we investigatedthestatus
Figure 3. (a) Scatterplot showing the gene expression
difference between the two patients. Threshold lines are set
to a 2-fold change. The left panel shows the data before
background filtering, while the right panel shows the data after
filtering. (b) Histogram showing expression data regarding the
selected genes by real-time RT-PCR. Normalization was
conducted on beta-actin.
Figure 4. (a) Agarose gel electrophoresis relative to MSP
products. Lines marked “U” contain products derived from
unmethylated DNA templates, whereas products amplified
from methylated templates are found in lines “M”.
(b) Primer sequences used in the methylation-specific
PCR to study the methylation status of the promoter of the
following genes: MGMT, p16, DCC and DAPK.
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methylated: the hypermethylated p16 promoter inhibited
its expression [4-7]. In Patient 2, an increase was found in
the EGFR copynumberwithits strongexpression andPTEN
mutation; these are all aberrations found in de novo
glioblastoma. Interestingly, we found a deletion of the
p27kip1 gene locus inboth patients, underlining the loss of
cell-cycle control. No aberrations were found in CDKN1A
(p21). We found altered expressions of several genes
involved in different cellular process such as those involved
in the transcriptional regulation of growth control, and
those involved in signal transduction cascades and cytoske-
leton related genes. Two angiogenesis related genes, well-
known in glioma biology, VCAM1 and VEGF,w e r e
overexpressed in Patient 2 reflecting the high degree of
neovascularization. Genes involved in drug resistance,
ABCC3 and metallothioneins, which could play a role in
drug resistance, were highly expressed in Patient 2’st u m o r
tissue, explaining his non-responsiveness to chemotherapy.
One hallmark of tumors is the lack of control of apoptosis
linked genes (CASP7, BCLW, DAP3), found to be down-
regulated in both tumors. The absence of DCC function,
associated with several types of tumors, appeared to also
affect our patients. Moreover, we investigated the methyla-
tion status of the DNA repair protein gene O6-methylgua-
nine-methyltransferase (MGMT), which is a marker of
resistance to chemotherapeutic alkylating agents, including
temozolomide (TMZ), in high-grade gliomas, particularly
glioblastomas [8]. Since the protein is able to repair DNA
lesionsinducedbyalkylatingfactors,methylationofMGMT
promoter (M-MGMT) results in better responsiveness to
treatment with M-MGMT favoring the alkylating agents
function; in fact, Everhard et al. found that M-MGMTP
patients had a significantly longer progression-free survival
after TMZ than U-MGMTP patients [9]. Our data confirm
such a correlation, in that Patient 1 with M-MGMT
responded to TMZ, while no response was observed in
Patient 2 with U-MGMT.
Conclusions
We report two cases of GC Type II carrying similar clinical
and histological patterns but with distinct molecular and
prognostic features. The poor prognosis of Patient 2 was
underlined by molecular analysis which showed over-
expression of the angiogenesis related genes VCAM1 and
VEGF, reflecting the high degree of neovascularization
present. Moreover, in the same patient, we found a high
expression of genes involved in drug resistance such as
ABCC3 (multidrug resistance protein 3, MRP3)a n d
metallothioneins, which could play a role in intrinsic drug
resistance, and, along with unmethylated MGMT status,
may explain the lack of response to chemotherapy and
overall poor prognosis of this patient. Current prognostic
stratification of GC Type II is mainly based on tumor grade
as assessed by the pathologist; our data, according to a few
literature reports, seem to suggest that molecular character-
izationisrequired inordertoprovide propersubtypingand
to identify targeted treatment strategies.
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